revenue $6.3M, net income -$67.3M. Generate Biomedicines posts H1 2026 loss as GB-0895 Phase 3 asthma trial ramps

Filed August 6, 2026 · Period ending June 30, 2026 · ~2 min read

Key Changes

• high

  Net loss widened 28% to $129.0M in H1 2026 (vs. $101.1M prior year) as R&D spending rose $15.6M to $122.1M, driven by $19.0M increase in GB-0895 Phase 3 asthma trial and CMC costs.

  MD&A: Operating Results verify on EDGAR →
• high

  IPO in March 2026 raised $369.3M net proceeds (25M shares at $16), alleviating prior going-concern doubt. Cash/marketable securities of $457.4M provide runway into H1 2028 under current operating plan; additional capital required thereafter.

  Notes: IPO and Liquidity verify on EDGAR →
• high

  GB-0895 (long-acting anti-TSLP antibody) advanced to pivotal Phase 3 trials for severe asthma, representing the most advanced program and nearest-term commercial opportunity. Two other candidates (GB-4362, GB-5267) in Phase 1.

  MD&A: Pipeline verify on EDGAR →